Genomic Solutions Signs License Agreement with Louisville Research Foundation

Apr 25, 2001, 01:00 ET from Genomic Solutions Inc.

    ANN ARBOR, Mich., April 25 /PRNewswire/ -- Genomic Solutions Inc.
 (Nasdaq:   GNSL), a leading, worldwide supplier of automated solutions for
 genomic and proteomic research, announces it has finalized a sponsorship
 agreement and exclusive license agreement with the University of Louisville
 Research Foundation.  The investigations, conducted by Drs. Jon and Elias
 Klein of the University's Medicine and Kidney Disease departments, involve
 development of the next generation of isoelectric focusing (IEF) technology
 that Genomic Solutions plans to commercialize through exclusive license rights
 in the life sciences research field.
     "In short, the Kleins' research group will develop technology variables
 that will help extend the shelf life and ease the use of IEF gels," says Greg
 Kinch, Director of Business Development for Genomic Solutions.  "We feel this
 'gel-in-a-shell' technology is an ideal candidate for commercialization -- and
 is a symbiotic fit with other products in our fully-integrated
 Investigator(TM) Proteomic System."
     Over the next six months, the main thrust of the research will be
 development and production of IEF gels in totally plastic tubing to confirm
 the benefits exhibited in bench scale testing, including superior ease of use
 and improved automation capabilities.  "Research sponsorship and licensing is
 another of our forward-looking strategies at Genomic Solutions," Kinch adds.
 "These types of partnerships help us further accelerate development of
 enabling technologies that researchers can use for more productive work, from
 basic life science research to drug discovery."
     Genomic Solutions Inc. designs, develops, manufactures, markets and sells
 instruments, software, consumables and services used to determine the activity
 level of genes and to isolate, identify and characterize proteins.  The
 company's products and systems enable researchers to perform complex, high
 volume experiments at a lower cost and in less time than traditional
 techniques.  As a result, Genomic Solutions products and systems facilitate
 more rapid and less expensive drug discovery.  Genomic Solutions markets
 products through its corporate headquarters in Ann Arbor, Michigan USA, and
 offices in San Diego, California USA and Japan.  Remaining worldwide
 distribution is provided by PerkinElmer Life Sciences through a strategic
 alliance with Genomic Solutions.  The two companies also cooperate to sell co-
 branded products and collaborate to leverage their intellectual property and
 technologies.
     Statements in this news release that are not strictly historical are
 "forward-looking" statements within the meaning of Section 27A of the
 Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
 These statements involve a high degree of risk and uncertainty that exist in
 the company's operations and business environment. Such statements are
 predictions only and actual events or results may differ materially from those
 projected in such forward-looking statements. Factors that could affect actual
 events or results include risks associated with performance under the
 company's agreements with third parties, research and development progress,
 competitive products and the strength of the company's patent portfolio. These
 factors and others are more fully described under "Risk Factors" in Genomic
 Solutions' Form 10-K for the year ended Dec. 31, 2000, and in Genomic
 Solutions' other filings with the Securities and Exchange Commission. The
 company expressly disclaims any obligation or undertaking to release publicly
 any updates for revisions to any forward-looking statements contained herein
 to reflect any change in the company's expectations with regard thereto or any
 change in events, conditions or circumstances on which any such statements are
 based.
     For more information, contact us at info@genomicsolutions.com or visit our
 Website, www.genomicsolutions.com .
 
                       MAKE YOUR OPINION COUNT -  Click Here
                  http://tbutton.prnewswire.com/prn/11690X65174033
 
 

SOURCE Genomic Solutions Inc.
    ANN ARBOR, Mich., April 25 /PRNewswire/ -- Genomic Solutions Inc.
 (Nasdaq:   GNSL), a leading, worldwide supplier of automated solutions for
 genomic and proteomic research, announces it has finalized a sponsorship
 agreement and exclusive license agreement with the University of Louisville
 Research Foundation.  The investigations, conducted by Drs. Jon and Elias
 Klein of the University's Medicine and Kidney Disease departments, involve
 development of the next generation of isoelectric focusing (IEF) technology
 that Genomic Solutions plans to commercialize through exclusive license rights
 in the life sciences research field.
     "In short, the Kleins' research group will develop technology variables
 that will help extend the shelf life and ease the use of IEF gels," says Greg
 Kinch, Director of Business Development for Genomic Solutions.  "We feel this
 'gel-in-a-shell' technology is an ideal candidate for commercialization -- and
 is a symbiotic fit with other products in our fully-integrated
 Investigator(TM) Proteomic System."
     Over the next six months, the main thrust of the research will be
 development and production of IEF gels in totally plastic tubing to confirm
 the benefits exhibited in bench scale testing, including superior ease of use
 and improved automation capabilities.  "Research sponsorship and licensing is
 another of our forward-looking strategies at Genomic Solutions," Kinch adds.
 "These types of partnerships help us further accelerate development of
 enabling technologies that researchers can use for more productive work, from
 basic life science research to drug discovery."
     Genomic Solutions Inc. designs, develops, manufactures, markets and sells
 instruments, software, consumables and services used to determine the activity
 level of genes and to isolate, identify and characterize proteins.  The
 company's products and systems enable researchers to perform complex, high
 volume experiments at a lower cost and in less time than traditional
 techniques.  As a result, Genomic Solutions products and systems facilitate
 more rapid and less expensive drug discovery.  Genomic Solutions markets
 products through its corporate headquarters in Ann Arbor, Michigan USA, and
 offices in San Diego, California USA and Japan.  Remaining worldwide
 distribution is provided by PerkinElmer Life Sciences through a strategic
 alliance with Genomic Solutions.  The two companies also cooperate to sell co-
 branded products and collaborate to leverage their intellectual property and
 technologies.
     Statements in this news release that are not strictly historical are
 "forward-looking" statements within the meaning of Section 27A of the
 Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
 These statements involve a high degree of risk and uncertainty that exist in
 the company's operations and business environment. Such statements are
 predictions only and actual events or results may differ materially from those
 projected in such forward-looking statements. Factors that could affect actual
 events or results include risks associated with performance under the
 company's agreements with third parties, research and development progress,
 competitive products and the strength of the company's patent portfolio. These
 factors and others are more fully described under "Risk Factors" in Genomic
 Solutions' Form 10-K for the year ended Dec. 31, 2000, and in Genomic
 Solutions' other filings with the Securities and Exchange Commission. The
 company expressly disclaims any obligation or undertaking to release publicly
 any updates for revisions to any forward-looking statements contained herein
 to reflect any change in the company's expectations with regard thereto or any
 change in events, conditions or circumstances on which any such statements are
 based.
     For more information, contact us at info@genomicsolutions.com or visit our
 Website, www.genomicsolutions.com .
 
                       MAKE YOUR OPINION COUNT -  Click Here
                  http://tbutton.prnewswire.com/prn/11690X65174033
 
 SOURCE  Genomic Solutions Inc.